Banner
Banner
Bioscreening Company Directory

Wyatt Technology Corp.

Wyatt Technology Corp. 6300 Hollister Ave
93117 Santa Barbara United States
Email: This e-mail address is being protected from spambots. You need JavaScript enabled to view it
Website
Quality at Wyatt Technology begins by listening attentively to our customers. We strive to make all customer contact with Wyatt Technology into a positive experience. Regardless of whether the customer issue is one of service, innovation or product quality, our aim is to delight the customer. We set and maintain the highest standards for production consistency, while incorporating flexibility and innovation into each process. We seek innovative ways to improve our work habits and adopt the best practices from wherever we find them, whenever we find them.

The inventors of the world's first multi-angle laser light scattering (MALS) instrument share a moment to celebrate their achievement.Some of the original Wyatt Scientists

The Wyatt Technology Corporation (WTC) is involved in the research, development, and commercialization of absolute macromolecular characterization techniques and their instrumentation. Founded in March 1982 by Dr. Philip Wyatt, the company was formed around his patents, ideas and inventions in industrial, military, and medical domains. To date, WTC has developed instruments capable of measuring the multi-angle light scattering characteristics of macromolecules (and particles) in solution, refractometers, as well as instruments for airborne aerosol monitoring and biodefense.

To a great extent, much of WTC's business began with the Small Business Innovation Research (SBIR) contracts awarded to the firm for its outstanding technological prowess and potential. The SBIR contracts are administered by certain agencies of the U.S. Government who have set aside a fraction of their authorized R&D funding for exclusive award to small businesses (a "small business" has fewer than 500 employees). The purpose of these highly competitive programs is to encourage scientific and technical innovation in areas deemed to be of national importance. The successful commercialization of products developed under these programs is one of the most important objectives of SBIR funding.

WTC has been awarded contracts from the U.S. Army Bioengineering Medical Research & Development Laboratory to establish the feasibility of instrumentation for the detection of toxicants in drinking water within sixty minutes. Another contract from the U.S. Army Armament, Munitions and Chemical Command to build an aerosol monitoring device for sub-micron particles. The potential applications for this instrument include real time identification of aerosol particles such as asbestos fibers and biological agents.

Another major contract was awarded by the Office of Naval Research, to develop an in situ particle monitoring device for characterizing undersea environments and their particulate constituents.

But by far, the company's commercial instruments, known by the trade name DAWN®, have been the driving force of the company in the 1990's. With extensive emphasis placed on intellectual property and new, patentable developments, the DAWN and miniDAWN systems have been sold in increasing numbers for more than a decade. Instruments have been placed in literally thousands of laboratories throughout the world, making them the most widely-recognized light scattering products on earth. The utility of the instruments is underscored by the burgeoning bibliography of publications, most of which have appeared in refereed journals. The DAWN systems provide unique and powerful tools for many different areas of analytical chemistry, including quality control, process control, molecular weight and size determinations, and a host of other applications, which are all possible with these multi-angle light scattering instruments.

The DAWN detectors are used by the world's most prestigious universities and some of the largest corporations in the world including DuPont, Dow, IBM, Glaxo, Unilever, Wyeth, Bayer and Merck. The company's applications have also involved sales to companies at the forefront of the biotechnology arena including Amgen, Genentech, Chiron, Genzyme, and Biogen.

Overseas sales provide an important component of the company's growth. Wyatt Technology actively sells its products throughout Europe, South America and Asia, thereby ensuring the greatest possible visibility and strongest sales potential for these systems. In 1993 Wyatt Technology formed Wyatt Technology Deutschland, a partially-owned subsidiary, to exploit the enormous sales in Germany and prepare for future sales into Eastern Europe. In March 2002, WTD began a new phase of its existence as Wyatt Technology Europe an entity capable of providing even higher levels of support and applications assistance throughout Europe.

A powerful distribution network ensures excellent service and support worldwide, while strategic partnerships with Agilent (as a member of their prestigious "Channel Partner" Program) and Waters Corporation, ensure Wyatt's compatibility with the industry-leading HPLC hardware.

Increasing marketing activities by WTC, both in the U.S. and abroad as well, has heightened universal awareness of the need for better analytical instruments, bode well for the Company's future. A Scientific Advisory Board comprised of two members of the National Academy of Science and several of the world's leading scholars in polymer chemistry, underscores the company's commitment to scientific excellence, as well as to world-wide acceptance of its products.

With direct sales and service facilities in Europe and the Eastern U. S., its Santa Barbara area home office contains over 30,000 square feet of modern electronics, optical prototype, machine shop, and laboratory facilities.

More than 30 years ago, Wyatt Technology's scientists invented the very first commercial light scattering instruments incorporating lasers as their light source. The US government was the first customer of these innovative technologies, designed to meet the need of specific applications including the detection of toxicants in drinking water and monitoring of particles in undersea environments (see our History). We've been defining and redefining the state-of-the-art laser light scattering hardware, software, training and services to meet customer needs for over two decades. Along the way we've added several related technologies to our product line including dynamic light scattering, refractometry, viscometry, and field flow fractionation.

Our attentiveness to customer needs and their applications has resulted in the installation of these novel technologies in more than 50 countries, making Wyatt Technology the world's leading manufacturer of laser light scattering instrumentation for absolute macromolecular characterization. It is the only company in the world focused exclusively on such systems, their design, and their application.

In fact, Wyatt Technology is one of the only manufacturers of light scattering instrumentation who develops its own hardware and software.

We stand behind every instrument we make, with engineering, service and support that are unmatched in the industry.

We seek innovative ways to improve the performance of our technologies, and set and maintain the highest production and quality standards to ensure each and every customer consistently receive the finest laser light scattering instrumentation.

Please begin your tour of Wyatt Technology's products by selecting Hardware and browsing through our complete product line of instruments and accessories for absolute macromolecular characterization.

Products

  • Protein Association System
  • Biomolecular Characterization
  • Chromatography Columns
  • Mobility Measurement
  • Refractive Index Detection Instrument

 


WaySearch
  
Powered by Sigsiu.NET RSS Feeds
ScienceDaily (May 16, 2012) — Microscopes provide valuable insights in the structure and dynamics of cells, in particular when the latter remain in their natural environment. However, this is very difficult especially for higher organisms. Researchers of Karlsruhe Institute of Technology (KIT), the Max Planck Institute for Polymer Research, Mainz, and the American National Institutes of Health (NIH) have now developed a new method to visualize cell structures of an eighth of a micrometer in size in living fish larvae. Read the Full Story
ScienceDaily (May 15, 2012) — Astrophysicists have just discovered a new heating source in cosmological structure formation. Until now, astrophysicists thought that super-massive black holes could only influence their immediate surroundings. A collaboration of scientists at the Heidelberg Institute for Theoretical Studies (HITS) and in Canada and the US have now discovered that diffuse gas in the universe can absorb luminous gamma-ray emission from black holes, heating it up strongly. This surprising result has important implications for the formation of structures in the universe. Read the Full Story
ScienceDaily (May 15, 2012) — Astrophysicists have just discovered a new heating source in cosmological structure formation. Until now, astrophysicists thought that super-massive black holes could only influence their immediate surroundings. A collaboration of scientists at the Heidelberg Institute for Theoretical Studies (HITS) and in Canada and the US have now discovered that diffuse gas in the universe can absorb luminous gamma-ray emission from black holes, heating it up strongly. This surprising result has important implications for the formation of structures in the universe. Read the Full Story
ScienceDaily (May 13, 2012) — Using tiny solar-panel-like cells surgically placed underneath the retina, scientists at the Stanford University School of Medicine have devised a system that may someday restore sight to people who have lost vision because of certain types of degenerative eye diseases. Read the Full Story
ScienceDaily (May 10, 2012) — A new study published in Science May 11 is shedding light on the molecular details of PARP-1, a DNA damage-detecting enzyme that when inhibited has been shown to be effective in fighting cancer and other diseases. Read the Full Story
ScienceDaily (May 14, 2012) — Prickly pufferfish could hold the key to why humans do not continually replace their teeth and may lead to advances in dental therapies. Read the Full Story
image Microscope Looks Into Cells of Living Fish
image Sulfur Finding May Hold Key to Gaia Theory of Earth as Living Organism
image Black Holes Turn Up the Heat for the Universe
image Tiny Solar-Panel-Like Cells Help Restore Sight to the Blind
image Why Inhibiting DNA Damage-Detecting Enzyme Is Effective in Fighting Cancer and Other Diseases
image Pufferfish at the 'Beak' of Evolution: Why Humans Don't Continuously Replace Their Teeth

BioScreening News

  • Evotec Becomes First European CRO to Offer Agilent’s RapidFire Screening Tool
    Evotec is adding Agilent Technologies’ RapidFire mass spectrometry analysis capabilities to its high-throughput screening facilities in Hamburg. RapidFire is an in-line solid-phase extraction technology. It enables ultrafast, direct analysis of native compounds for a variety of biochemical assays including routine ADME and lead discovery applications across a range of therapeutic...
  • Pfizer’s Torisel Misses Endpoints in Renal Cell Carcinoma Trial Testing Second-Line Setting
    Pfizer’s drug candidate for advanced renal cell carcinoma (RCC), Torisel, failed to meet the primary endpoint of progression-free survival in the Phase III Intorsect study. The trial compared Torisel and Nexavar in patients whose disease had progressed on or after treatment with the company’s approved drug Sutent. Although PFS was...
  • Lonza, Avalanche Partner on Baculovirus-Based AAV Manufacturing Platform
    Biologics manufacturer Lonza and ocular gene therapy specialist Avalanche Biotechnologies established a global manufacturing collaboration to aid in the latter’s gene therapy programs. Avalanche’s lead wet age-related macular degeneration (wet-AMD) gene therapy candidate AVA-101 started in early clinical trials at the end of 2011. The partnership will focus on the...
  • IntelligentMDx Wins CE Mark for Group B Strep Assay on Abbott m2000 Instrument
    IntelligentMDx received a CE Mark for its qualitative Group B Streptococcus (GBS) in vitro diagnostic, IMDx GBS, for use on the Abbott m2000™ system. The assay is used to screen for Group B Streptococcus infection in at-risk pregnant women and women in labor. The real-time PCR test can be carried...
  • Admescope to Provide PlexPress Multiplex CYP Gene Expression Analysis Technology
    CRO Admescope will offer PlexPress’ TRAC (transcript analysis with the aid of affinity capture) platform for high-throughput gene expression analysis as part of its in vitro drug interaction and preclinical ADME-Tox services. Finland-based Admescope will initially offer Plexpress’ multiplex cytochrome P450 (CYP) assays. The firm says the service will meet...
  • Six Suitors Join Bristol-Myers in Considering a Bid for Amylin
    After turning down an unsolicited bid from Bristol-Myers Squibb (BMS) in February, Amylin Pharmaceuticals is preparing to weigh offers from BMS and up to six other potential suitors. Citing unnamed “people familiar with the matter,” Bloomberg News reported that BMS has joined AstraZeneca, Merck & Co., Pfizer, Roche, Sanofi, and...
  • Accelr8, Denver Health Win $2M to Develop Battlefield Infections Diagnostic
    Accelr8 and Denver Health received notification that the Defence Medical Research and Development Program (DMRPD) has recommended a $2 million award to support a three-year project focused on developing a rapid diagnostic system for wound infections and serious infections secondary to trauma. The project was the sole recipient of funds...
  • Gamida Cell Raises $10M to Progress Phase III-Stage Hematologic Cancer Cell Therapy
    Gamida Cell raised $10 million through an internal Series E financing round with all its existing major shareholders. The proceeds will be used to support global commercialization of the firm’s Phase III-stage StemEx cord blood stem cell therapy for blood cancers, and continue development of additional pipeline candidates, including clinical...
  • ALS Institute, Neurotune to Evaluate Amyotrophic Lateral Sclerosis Therapeutic Candidate
    The ALS Therapeutic Institute and Neurotune established a collaboration to evaluate one of the latter’s neuromuscular diseases candidates in an ALS disease model. ALS is associated with motor neurons and their axons becoming disconnected from muscle, and Neurotune has identified a class of compounds designed to maintain neuromuscular junction strength...
  • KineMed, CHDI Ally on Biomarkers of Huntington Disease Progression, Drug Efficacy
    CHDI Foundation and KineMed established a collaboration to exploit the latter’s tandem mass spectrometry-based proteomics platform to analyze the in vivo dynamics of mutant huntingtin protein as a means of assessing Huntington disease progression and measuring the efficacy of therapeutic candidates. The aim is to generate data that will both...

Life Science Events

April 2012 May 2012 June 2012
Su Mo Tu We Th Fr Sa
1 2 3 4 5
6 7 8 9 10 11 12
13 14 15 16 17 18 19
20 21 22 23 24 25 26
27 28 29 30 31
Recent events
View full calendar
1 DOW 12,548.33
-50.22 (-0.40%)    
2 S&P 1,316.14
-8.66 (-0.65%)    
3 NASDAQ 2,843.84
-30.20 (-1.05%)